New recommendations Open recommendations Open ...

Model Portfolio update - ICICI Direct

Performance so far* …Deal Team –At Your Service Source:ThomsonReuters,ICICIDirectResearch •Our indicative large cap equity model portfolio has continued to deliver an

  Model, Portfolio, Model portfolio

8 e A l 0 0 0 y Momentum Picks - ICICI Direct

ties – esearch PICK NSE (Nifty): 10957 Equity benchmarks witnessed range bound activity as the Nifty ended the session at 10957, down 23 points or 0.2%.

  Pick, 0 0 0, Momentum picks, Momentum

2.2% 1.8% 1.7% 1.3% 1,270.4 1,128.7 503.2 265.8 …

ICICI Securities Ltd. | Retail Equity Research July 23, 2018 Opening Bell Market Outlook levels would remain the key things to watch. Stock specific movements could be s

  Market, Outlook, Market outlook

Powerpoint Guidelines Presentation - ICICI Direct

5 Research catering to client needs Short term Trading Medium term Investing Long term Investing Fundamentals Intra –day Trading Momentum Technicals

  Guidelines, Presentation, Powerpoint, Powerpoint guidelines presentation

SCHEME PRODUCT SUITABILITY RISKOMETER

PRODUCT LABELLING: OPEN ENDED INCOME SCHEMES SCHEME PRODUCT SUITABILITY RISKOMETER DSP BlackRock Bond Fund DSP BlackRock Constant Maturity 10Y G-Sec Fund

* Closing Price of July 24, 2018 - ICICI Direct

ies – esearch ICK • BSE consumer goods moved within the leading quadrant. Consumer goods stocks have seen strong momentum last month, which is likely to continue.

  Consumer

May 2018 - ICICI Direct

Product range (Minimum Recommended Investment Period (MRIP) 1 day Liquid 3months 1 year 2 years 3 years 4 years 5 years Arbitrage Hybrid Funds Diversified Funds

  Product, Ranges, Year, Minimum, Recommended, Product range, Minimum recommended

Fund Speak, May 2018 - ICICI Direct

Type of Scheme Investment Objective Fund Manager** Allotment Date Benchmark Index Minimum Investment Amount Systematic Investment Plan (SIP) Load Structure

Daily Currency outlook - ICICI Direct

ies – esearch Research Analysts Amit Gupta amit.gup@icicisecurities.com Gaurav Shah Gaurav.shah@icicisecurities.com • PRODUCT 2 • PRODUCT 1 Daily Currency outlook

  Outlook, Currency, Daily, Daily currency outlook

Investor Pathway Brochure - ICICI Direct

ICICI Centre for Financial Learning is a part of ICICI Securities Ltd.( I-Sec). Registered office of I-Sec is at ICICI Securiti es Ltd. - ICICI Centre, H. T. Parekh Marg, Churchgate, Mumbai - 400020, India, Tel No : 022 - 2288 2460, 022 - 2288 2470.

  Pathway, Investor, Investor pathway, Parekh

Medicinal Products Regulation in Brazil

• RDC 200/2017 – inclusion of some types of innovation • RDC 204/2017 – Priority Pathway ... • Approval before FDA and EMA in 2 cases (new therapeutic indication – daratumumab and pembrolizumab) ... (e.g. control strategy, manufacturing, study models, inclusion criteria)

  Product, Regulations, Strategy, Medicinal, Brazil, Medicinal products regulation in brazil

50 Pips A Day Forex Strategy - FXN Trading

200 EMA From my experience, this moving average is the only indicator that is worth incorporating in your trading system. It is the most important moving average of them all, all retail and professional traders keep an eye on it therefore price tends to bounce when it touches it. However, it is best to use it in your

  Strategy, 200 ema

Energy Measurement & Audit

primary strategy to reduce our carbon footprint and energy cost, and improve our energy resilience is to improve our energy efficiency. One of the fundamental actions required to improve energy efficiency is to measure and verify how efficiently energy is being used. The data from accurate measurement will provide the

  Strategy

Novartis Annual Report 2019

Delivering on our strategy supported our financial per-formance in 2019. Strength in key products helped us post net sales of USD 47.4 billion, up 9%, measured in constant currencies (cc). Our core operating income rose 17% (cc) to USD 14.1 billion, increasing core margin by 1.9 percentage points (cc) to 29.7%.

  Annual, Report, Strategy, Novartis, Novartis annual report

molnupiravir COVID19-MSD - Assessment Report

Molnupiravir is presented for clinical use as a 200 mg hard capsule for oral administration. The ... their carryover and control strategy has been provided and is acceptable, supporting the . ... nitrosamine impurities currently listed in EMA guidance have been considered and no risks could be identified. Characterisation data for specified ...

  Strategy

(Text with EEA relevance)

primary series, or, in line with the vaccination strategy of the Member State of vaccination, a single dose primary course of a two-dose vaccine after having previously been infected with SARS-CoV-2. Vaccination certificates issued after the first dose of …

  Strategy

Number of parameters (M)

assignment strategy SimOTA to achieve state-of-the-art re-sults across a large scale range of models: For YOLO-Nano with only 0.91M parameters and 1.08G FLOPs, we get 25.3% AP on COCO, surpassing NanoDet by 1.8% AP; for YOLOv3, one of the most widely used detectors in in-dustry, we boost it to 47.3% AP on COCO, outperform-

  Strategy

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Each vial contains 200 mg of tocilizumab* in 10 mL (20 mg/mL). Each vial contains 400 mg of tocilizumab* in 20 mL (20 mg/mL). *humanised IgG1 monoclonal antibody against the human interleukin-6 (IL-6) receptor produced in Chinese hamster ovary (CHO) cells …